Comparison Of The Clinical Efficacy Of Levofloxacin Sequential Therapy And Azithromycin Sequential Therapy In Treatment Of Community-acquired Pneumonia: A Randomized Controlled Study

Objective:To evaluate the clinical efficacy and safety of sequential therapy with azithromycin and levofloxacin in treatment of community-acquired pneumonia (CAP).Methods:91 patients with community-acquired pneumonia were divided randomly into the levofloxacin group (45 cases) and azithromycin group (46 cases). The levofloxacin group were treated with levofloxacin 0.4g intravenously once a day for 3～5days, and sequentially changed to oral administration for 5～7days. The azithromycin group were treated with azithromycin 0.5g intravenously once a day for 3～5days, and sequentially changed to oral administration for 5-7days.In both groups the observation of curative effects and safety were conducted.Results:The curative rate of levofloxacin group and azithromycin group were 82.2% and 67.4% respectively, and the differences between two groups were statistical significance (p<0.05). The effective rate of levofloxacin group and azithromycin group were 93.3% and 83.3% respectively, and the differences between two groups were statistical significance (p<0.05). The bacterial eradication rate of levofloxacin group and azithromycin group were 95.6% and 79.2% respectively, and the differences between two groups were statistical significance (p<0.05). The incidence of drug adverse reaction of levofloxacin group and azithromycin group were 11.1% and 10.9% respectively, and there were no significant differences in results between the two groups of treatment (p>0.05)Conclusions:Sequential therapy of levofloxacin has better curative rate and bacterial eradication rate than that of azithromycin in treatment of CAP. Levofloxacin and azithromycin are safety.